Pharma & Biotech Patent Litigation

Conference Day 1: 31st January 2012

8.30 Coffee and Registration

8.50 Chair’s Opening Remarks
Gareth Morgan, Partner, Winston & Strawn (UK)

9.00 Keynote Address
Recent Case Law Developments in Pharma and Biotech Patent Litigation in Germany
Karin Friehe,Judge, Federal Patent Court, Munich (Germany)

9.30 SPC References and Recent Opinion by theAdvocate General of the ECJ: What You Needto Know for Your SPC Applications
Juergen Dressel, Head of Patent Litigation ex USA, Novartis (Switzerland)

10.15 The Enforceability of Gene Sequence Patentsin Light of Lilly v HGS
Gareth Morgan, Partner, Winston & Strawn (UK)

11:00 Refreshment Break

11.15 EPO Update on Biotech Patenting and theEU Patent Reform
Eleni Kossonakou, Directorate Patent Law, European Patent Office (Germany)

12.00 Limiting Protection for Biotech Inventions – a Trend?
Michael Kock, Global Head IP, Syngenta International AG (Switzerland)

• Recent referrals to the ECJ on the scope of claims for nucleic acids
  - impact of new interpretation on EU national laws relating to the scope of protection
  - how can practitioners circumvent the decision for patents granted that are based on such claims?
• Patentability of biological processes for breeding plants
  - G2/07 (“Broccoli Case”)
  - G1/08 (“Tomato Case”)
  - exemptions for essentially biological processes
• Impact on swine breeding and breeding of animals
• Achieving improved plants based on smart breeding (breeding based on molecular analysis)
  

12.45 Lunch

13.35 Panel Session: The Impact of Recent Launch Strategies byGenerics on Preliminary and Interim Injunctions

Across Europe
Moderator: Philip Carey, Associate, Winston & Strawn (UK)
Julia Pike, Head of Global IP Litigation, Sandoz (Germany) Marleen H.J. van den Horst, Partner, Head of IP & Technology Practice Group, BarentsKrans (Netherlands)

14.40 Recent US Developments in Pharmaand Biotech Patent Litigation
Colleen Tracy, Partner, Fitzpatrick, Cella, Harper & Scinto (US)

15.30 Refreshment Break

15.45 Patentability and Enforcement of Research ToolPatents: How Broadly Should Reach-ThroughClaims be Applied?
Huw Evans, Partner, Allen & Overy LLP

16.30 Patent Litigation in India for Pharma& Biotech Products
R. Parthasarathy, Senior Partner, Head of IPR Division,
Lakshmikumaran & Sridharan Attorneys (India)

17.15 Chairman’s Closing Remarks and End of Day One

Conference Day 2: 1st February 2012February 2012

8.45 Chair’s Opening Remarks
Colleen Tracy, Partner, Fitzpatrick, Cella, Harper & Scinto (US)

8.50 Instructing Scientific Experts in your PatentLitigation Proceedings in Light of Recent Case Law
Paul Inman, Partner, Wragge & Co. (UK)
Dr. Jan-Hendrik Spilgies, Partner, Hoffmann-Eitle
Peter-Ulrik Plesner, Partner, Plesner (Denmark)

9.50 Patent Litigation Strategies in Centraland Eastern Europe

• Poland
• Hungary
• Russia
• Czech Republic

Dr. Árpád Petho, Partner, Danubia Patent & Law Office LLC (Hungary)
Ewa Rutkowska, Partner, Baker & McKenzie Krzyzowski & Partners (Poland)
Vladislav Ugryumov, Partner, Gowlings (Russia)
Petr Kusý, Patent Attorney, Čermák a spol. Law and Patent Offices (Czech Republic)

11.00 Refreshment Break

11.15 Second Medical Use and Dosing Regimens Claims: Back in the Spotlight
Dr Fiona Bor, Director of IP, Mylan (UK)
Dr. Duncan Curley, Director, Innovate Legal (UK)

11.55 Developing a Successful Strategy for Pan-European Patent Enforcement Following Recent Case Law Developments on Cross-Border Injunctions
Simon Dack, Partner, Hoyng Monegier (Netherlands)
Alan Johnson, Partner, Bristows (UK)
Dr. Ewan Nettleton, Senior Patent Counsel, CVM,
Novartis Pharma AG (Switzerland)

12.55 Lunch

14.00 Disclosure of Prior Art and Forthcoming Antitrust Issues
Bernard McDonald, Global IP Manager, Legal Affairs Group, Emergent BioSolutions (UK)
Sean-Paul Brankin, Counsel, Crowell & Moring (Belgium)

14.50 The Stem Cell Patent Landscape: Overcoming the Legal and Regulatory Challenges
Dr. Jürgen Meier, Partner, Vossius & Partner (Germany)

15.30 Refreshment Break

15.45 Avoiding Patent Infringements in Clinical Trials
James Horgan, Assistant Counsel, European Patents, Merck & Co. Inc. (UK)

16.25 Managing the Practical Implications of EU Border Enforcement of IP Rights
Gertjan Kuipers, Partner, De Brauw Blackstone Westbroek (Netherlands)

17.10 Chairman’s Closing Remarks and End of Conference

- Actions -

- Share -